Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 137 articles:
HTML format
Text format



Single Articles


    December 2018
  1. RADES D, Panzner A, Janssen S, Dunst J, et al
    Outcomes After Radiotherapy Alone for Metastatic Spinal Cord Compression in Patients with Oligo-metastatic Breast Cancer.
    Anticancer Res. 2018;38:6897-6903.
    PubMed     Text format     Abstract available


  2. MANOUCHEHRI JM, Kalafatis M
    Ursolic Acid Promotes the Sensitization of rhTRAIL-resistant Triple-negative Breast Cancer.
    Anticancer Res. 2018;38:6789-6795.
    PubMed     Text format     Abstract available


  3. OLIVA D, Nilsson M, Strandeus M, Andersson BA, et al
    Individual Genetic Variation Might Predict Acute Skin Reactions in Women Undergoing Adjuvant Breast Cancer Radiotherapy.
    Anticancer Res. 2018;38:6763-6770.
    PubMed     Text format     Abstract available


  4. ORSARIA P, Chiaravalloti A, Caredda E, Marchese PV, et al
    Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Anticancer Res. 2018;38:6639-6652.
    PubMed     Text format     Abstract available


  5. GERA R, Tayeh S, Chehade HE, Mokbel K, et al
    Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:6615-6620.
    PubMed     Text format     Abstract available


    November 2018
  6. STEFANOU D, Kokkali S, Tripodaki ES, Drizou M, et al
    Subcutaneous Trastuzumab Combined with Pertuzumab and Docetaxel as First-line Treatment of Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:6565-6569.
    PubMed     Text format     Abstract available


  7. SAKAGUCHI M, Maebayashi T, Aizawa T, Ishibashi N, et al
    Whole-brain Radiation Therapy for Breast Cancer Patients with Dural Metastasis Without Concomitant Brain Metastasis and Leptomeningeal Metastasis.
    Anticancer Res. 2018;38:6405-6411.
    PubMed     Text format     Abstract available


  8. FU S, Lin J
    Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
    Anticancer Res. 2018;38:6271-6279.
    PubMed     Text format     Abstract available


  9. DU X, Klaschik K, Mallmann P, Isachenko E, et al
    An Experimental Model of Breast Cancer Cells: Informative Protocol for In Vitro Culture.
    Anticancer Res. 2018;38:6237-6245.
    PubMed     Text format     Abstract available


  10. SHI H, Liu J, Tu Y, Freter CE, et al
    Oolong Tea Extract Induces DNA Damage and Cleavage and Inhibits Breast Cancer Cell Growth and Tumorigenesis.
    Anticancer Res. 2018;38:6217-6223.
    PubMed     Text format     Abstract available


  11. TOROPOV AA, Toropova AP
    Predicting Cytotoxicity of 2-Phenylindole Derivatives Against Breast Cancer Cells Using Index of Ideality of Correlation.
    Anticancer Res. 2018;38:6189-6194.
    PubMed     Text format     Abstract available


  12. MUSA MA, Badisa VLD, Latinwo LM, Ntantie E, et al
    7,8-Dihydroxy-3-arylcoumarin Induces Cell Death Through S-Phase Arrest in MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2018;38:6091-6098.
    PubMed     Text format     Abstract available


  13. LUCCHETTI J, Formica V, Giuliano G, Coletta D, et al
    Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia.
    Anticancer Res. 2018;38:6561-6564.
    PubMed     Text format     Abstract available


  14. KORDONI M, Rigakos G, Kim YHM, Kaklamanis L, et al
    Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer.
    Anticancer Res. 2018;38:6439-6444.
    PubMed     Text format     Abstract available


    October 2018
  15. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  16. KONDO Y, Fukuyama T, Yamamura R, Futawatari N, et al
    Detection of KK-LC-1 Protein, a Cancer/Testis Antigen, in Patients with Breast Cancer.
    Anticancer Res. 2018;38:5923-5928.
    PubMed     Text format     Abstract available


  17. DUTTA D, Russell C, Kim J, Chandra S, et al
    Differential Mobility of Breast Cancer Cells and Normal Breast Epithelial Cells Under DC Electrophoresis and Electroosmosis.
    Anticancer Res. 2018;38:5733-5738.
    PubMed     Text format     Abstract available


  18. ICHIHARA H, Okumura M, Tsujimura K, Matsumoto Y, et al
    Theranostics with Hybrid Liposomes in an Orthotopic Graft Model Mice of Breast Cancer.
    Anticancer Res. 2018;38:5645-5654.
    PubMed     Text format     Abstract available


  19. FREEMAN J, Crowley PD, Foley AG, Gallagher HC, et al
    Effect of Perioperative Lidocaine and Cisplatin on Metastasis in a Murine Model of Breast Cancer Surgery.
    Anticancer Res. 2018;38:5599-5606.
    PubMed     Text format     Abstract available


    September 2018
  20. BONZANO E, Belgioia L, Fregatti P, Friedman D, et al
    Tumor Size-driven Dose of Intraoperative Radiotherapy for Breast Cancer: 18 Gy Versus 21 Gy.
    Anticancer Res. 2018;38:5475-5479.
    PubMed     Text format     Abstract available


  21. NAKATSUKASA K, Ouchi Y, Sakaguchi K, Goto M, et al
    Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.
    Anticancer Res. 2018;38:5459-5463.
    PubMed     Text format     Abstract available


  22. JOO JH, Kim SS, Son BH, DO Ahn S, et al
    Evaluation of the Prognostic Stage in the 8th Edition of the American Joint Committee on Cancer in Patients with Breast Cancer and Internal Mammary Lymph Node Metastasis.
    Anticancer Res. 2018;38:5357-5361.
    PubMed     Text format     Abstract available


  23. ZHOU M, Peddi P, Chu QD
    Radiation Therapy for Positive Surgical Margins in Women >/=70 Years with Stage I, Estrogen Receptor-positive Breast Cancer.
    Anticancer Res. 2018;38:5253-5260.
    PubMed     Text format     Abstract available


  24. WILHELM CA, Clor ZJ, Kelts JL
    Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:5043-5048.
    PubMed     Text format     Abstract available


  25. LEBLANC N, Harquail J, Crapoulet N, Ouellette RJ, et al
    Pax-5 Inhibits Breast Cancer Proliferation Through MiR-215 Up-regulation.
    Anticancer Res. 2018;38:5013-5026.
    PubMed     Text format     Abstract available


  26. PARK HL, Pyo YC, Kim KY, Park JS, et al
    Recurrence Rates and Characteristics of Phyllodes Tumors Diagnosed by Ultrasound-guided Vacuum-assisted Breast Biopsy (VABB).
    Anticancer Res. 2018;38:5481-5487.
    PubMed     Text format     Abstract available


    August 2018
  27. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer.
    Anticancer Res. 2018;38:4927-4931.
    PubMed     Text format     Abstract available


  28. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Text format     Abstract available


  29. MOKBEL K, Wazir U, Wazir A, Kasem A, et al
    The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER(+)/HER2(-) Breast Cancer Stratified as Having Moderate or Poor Prognosis by Nottingham Prognostic Index.
    Anticancer Res. 2018;38:4747-4752.
    PubMed     Text format     Abstract available


  30. FERRONI P, Roselli M, Buonomo OC, Spila A, et al
    Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer.
    Anticancer Res. 2018;38:4705-4712.
    PubMed     Text format     Abstract available


  31. WINSKA P, Skierka K, Lukowska-Chojnacka E, Koronkiewicz M, et al
    Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
    Anticancer Res. 2018;38:4617-4627.
    PubMed     Text format     Abstract available


  32. YEH MH, Tzeng YJ, Fu TY, You JJ, et al
    Extracellular Matrix-receptor Interaction Signaling Genes Associated with Inferior Breast Cancer Survival.
    Anticancer Res. 2018;38:4593-4605.
    PubMed     Text format     Abstract available


  33. RABACOW APM, Meza A, DE Oliveira EJT, DE David N, et al
    Evaluation of the Antitumor Potential of the Resorcinolic Lipid 3-Heptyl-3,4,6-trimethoxy-3H-isobenzofuran-1-one in Breast Cancer Cells.
    Anticancer Res. 2018;38:4565-4576.
    PubMed     Text format     Abstract available


  34. KENAN ES, Friger M, Shochat-Bigon D, Schayek H, et al
    Accuracy of Risk Prediction Models for Breast Cancer and BRCA1/BRCA2 Mutation Carrier Probabilities in Israel.
    Anticancer Res. 2018;38:4557-4563.
    PubMed     Text format     Abstract available


  35. MASUDA T, Shinden Y, Noda M, Ueo H, et al
    Circulating Pre-microRNA-488 in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
    Anticancer Res. 2018;38:4515-4523.
    PubMed     Text format     Abstract available


  36. BOMMAREDDY A, Knapp AWK, Nemeth A, Steigerwalt J, et al
    Alpha-Santalol, a Component of Sandalwood Oil Inhibits Migration of Breast Cancer Cells by Targeting the beta-catenin Pathway.
    Anticancer Res. 2018;38:4475-4480.
    PubMed     Text format     Abstract available


  37. HUNKE M, Martinez W, Kashyap A, Bokoskie T, et al
    Antineoplastic Actions of Cinnamic Acids and Their Dimers in Breast Cancer Cells: A Comparative Study.
    Anticancer Res. 2018;38:4469-4474.
    PubMed     Text format     Abstract available


  38. ANDING AL, Jones JD, Newton MA, Curley RW Jr, et al
    4-HPR Is an Endoplasmic Reticulum Stress Aggravator and Sensitizes Breast Cancer Cells Resistant to TRAIL/Apo2L.
    Anticancer Res. 2018;38:4403-4416.
    PubMed     Text format     Abstract available


  39. CAZZANIGA M, Bonanni B
    Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine?
    Anticancer Res. 2018;38:4393-4402.
    PubMed     Text format     Abstract available


  40. SPRAVE T, Verma V, Forster R, Schlampp I, et al
    Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial.
    Anticancer Res. 2018;38:4961-4968.
    PubMed     Text format     Abstract available


  41. HUANG FJ, Hung CC, Chang CW, Chao JH, et al
    Evaluation of Injectable Chitosan-based Co-cross-linking Hydrogel for Local Delivery of (188)Re-LIPO-DOX to Breast-tumor-bearing Mouse Model.
    Anticancer Res. 2018;38:4651-4659.
    PubMed     Text format     Abstract available


  42. EMMANUEL N, Lofgren KA, Peterson EA, Meier DR, et al
    Mutant GATA3 Actively Promotes the Growth of Normal and Malignant Mammary Cells.
    Anticancer Res. 2018;38:4435-4441.
    PubMed     Text format     Abstract available


    July 2018
  43. MORI H, Kubo M, Kai M, Kurata K, et al
    Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients.
    Anticancer Res. 2018;38:4381-4386.
    PubMed     Text format     Abstract available


  44. TANAKA T, Uchida H
    Inhibition of Survivin by Adenovirus Vector Enhanced Paclitaxel-induced Apoptosis in Breast Cancer Cells.
    Anticancer Res. 2018;38:4281-4288.
    PubMed     Text format     Abstract available


  45. KUBO M, Umebayashi M, Kurata K, Mori H, et al
    Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:4273-4279.
    PubMed     Text format     Abstract available


  46. SAKAGUCHI K, Nakatsukasa K, Koyama H, Kato M, et al
    Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:4073-4081.
    PubMed     Text format     Abstract available


  47. CHIANG KC, Yeh CN, Yeh TS, Juang HH, et al
    MART-10, a 1alpha,25(OH)2D3 Analog, Potently Represses Metastasis of ER(+) Breast Cancer Cells with VEGF-A Overexpression.
    Anticancer Res. 2018;38:3879-3887.
    PubMed     Text format     Abstract available


  48. TORATA N, Kubo M, Miura D, Ohuchida K, et al
    Visualizing Energy Charge in Breast Carcinoma Tissues by MALDI Mass-spectrometry Imaging Profiles of Low-molecular-weight Metabolites.
    Anticancer Res. 2018;38:4267-4272.
    PubMed     Text format     Abstract available


  49. FERDOVA E, Baxa J, Narsanska A, Hes O, et al
    Low-dose High-resolution (18)F-FDG-PET/CT Using Time-of-flight and Point-spread Function Reconstructions: A Role in the Detection of Breast Carcinoma Axillary Lymph Node Metastases.
    Anticancer Res. 2018;38:4145-4148.
    PubMed     Text format     Abstract available


  50. GRUBER I, Henzel M, Schonfisch B, Stabler A, et al
    Prediction of Non-sentinel Lymph Node Metastases After Positive Sentinel Lymph Nodes Using Nomograms.
    Anticancer Res. 2018;38:4047-4056.
    PubMed     Text format     Abstract available


    June 2018
  51. MALTER W, Hellmich M, Badian M, Kirn V, et al
    Factors Predictive of Sentinel Lymph Node Involvement in Primary Breast Cancer.
    Anticancer Res. 2018;38:3657-3662.
    PubMed     Text format     Abstract available


  52. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Text format     Abstract available


  53. LI J, Zhang J, Jin L, Deng H, et al
    Silencing lnc-ASAH2B-2 Inhibits Breast Cancer Cell Growth via the mTOR Pathway.
    Anticancer Res. 2018;38:3427-3434.
    PubMed     Text format     Abstract available


  54. CHOE MH, Kim J, Ahn J, Hwang SG, et al
    Centrosome Clustering Is a Tumor-selective Target for the Improvement of Radiotherapy in Breast Cancer Cells.
    Anticancer Res. 2018;38:3393-3400.
    PubMed     Text format     Abstract available


  55. DANDAMUDI A, Tommie J, Nommsen-Rivers L, Couch S, et al
    Dietary Patterns and Breast Cancer Risk: A Systematic Review.
    Anticancer Res. 2018;38:3209-3222.
    PubMed     Text format     Abstract available


  56. ASANO M, Matsui J, Towle MJ, Wu J, et al
    Broad-spectrum Preclinical Antitumor Activity of Eribulin (Halaven(R)): Combination with Anticancer Agents of Differing Mechanisms.
    Anticancer Res. 2018;38:3375-3385.
    PubMed     Text format     Abstract available


  57. RUSAK A, Jablonska K, Piotrowska A, Grzegrzolka J, et al
    The Role of CHI3L1 Expression in Angiogenesis in Invasive Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:3357-3366.
    PubMed     Text format     Abstract available


    May 2018
  58. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Text format     Abstract available


  59. LUMACHI F, Basso SMM, Camozzi V, Spaziante R, et al
    Bone Mineral Density as a Potential Predictive Factor for Luminal-type Breast Cancer in Postmenopausal Women.
    Anticancer Res. 2018;38:3049-3054.
    PubMed     Text format     Abstract available


  60. GOTO W, Kashiwagi S, Asano Y, Takada K, et al
    Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
    Anticancer Res. 2018;38:2929-2938.
    PubMed     Text format     Abstract available


  61. KORONOWICZ AA, Drozdowska M, Banks P, Piasna-Slupecka E, et al
    Fatty Acids of CLA-enriched Egg Yolks Can Induce Mitochondrial Pathway of Apoptosis in MCF-7 Breast Cancer Cells.
    Anticancer Res. 2018;38:2861-2870.
    PubMed     Text format     Abstract available


  62. MINAFRA L, Bravata V, Cammarata FP, Russo G, et al
    Radiation Gene-expression Signatures in Primary Breast Cancer Cells.
    Anticancer Res. 2018;38:2707-2715.
    PubMed     Text format     Abstract available


  63. REINHARDT A, Liu H, Ma Y, Zhou Y, et al
    Tumor Cell-selective Synergism of TRAIL- and ATRA-induced Cytotoxicity in Breast Cancer Cells.
    Anticancer Res. 2018;38:2669-2682.
    PubMed     Text format     Abstract available


  64. TUNGSUKRUTHAI S, Petpiroon N, Chanvorachote P
    Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds.
    Anticancer Res. 2018;38:2607-2618.
    PubMed     Text format     Abstract available


  65. LEHMANN-CHE J, Miquel C, Wong J, Callens C, et al
    First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.
    Anticancer Res. 2018;38:2909-2914.
    PubMed     Text format     Abstract available


  66. LIU LC, Wu YC, Kuo SC, Ho CT, et al
    2-Phenylnaphthyridin-4-one Derivative LYF-11 Inhibits Interleukin-6-mediated Epithelial-to-Mesenchymal Transition via the Inhibition of JAK2/STAT3 Signaling Pathway in MCF-7 Cells.
    Anticancer Res. 2018;38:2849-2859.
    PubMed     Text format     Abstract available


  67. TATARA T, Mukohara T, Tanaka R, Shimono Y, et al
    3D Culture Represents Apoptosis Induced by Trastuzumab Better than 2D Monolayer Culture.
    Anticancer Res. 2018;38:2831-2839.
    PubMed     Text format     Abstract available


  68. OKARVI SM, Aljammaz I
    Preparation and In Vitro and In Vivo Characterization of the Tumor-specific Antigen-derived Peptide as a Potential Candidate for Targeting Human Epidermal Growth Factor Receptor 2-positive Breast Carcinomas.
    Anticancer Res. 2018;38:2823-2830.
    PubMed     Text format     Abstract available


    April 2018
  69. INOUE Y, Yamashita N, Ueo H, Tanaka K, et al
    The Clinical Usefulness of the LigaSure Small Jaw in Axillary Lymph Node Dissection in Patients with Breast Cancer.
    Anticancer Res. 2018;38:2359-2362.
    PubMed     Text format     Abstract available


  70. ASANO Y, Kashiwagi S, Goto W, Takada K, et al
    Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Anticancer Res. 2018;38:2311-2321.
    PubMed     Text format     Abstract available


  71. TAKADA K, Kashiwagi S, Goto W, Asano Y, et al
    Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Anticancer Res. 2018;38:2285-2294.
    PubMed     Text format     Abstract available


  72. TUOHINEN SS, Keski-Pukkila K, Skytta T, Huhtala H, et al
    Radiotherapy-induced Early ECG Changes and Their Comparison with Echocardiography in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2018;38:2207-2215.
    PubMed     Text format     Abstract available


  73. HSIAO CL, Liu LC, Shih TC, Chuang CL, et al
    The Association of Matrix Metalloproteinase-8 Promoter Genotypes in Breast Cancer.
    Anticancer Res. 2018;38:2181-2185.
    PubMed     Text format     Abstract available


  74. ORSARIA P, Caredda E, Genova F, Materazzo M, et al
    Additional Nodal Disease Prediction in Breast Cancer with Sentinel Lymph Node Metastasis Based on Clinicopathological Features.
    Anticancer Res. 2018;38:2109-2117.
    PubMed     Text format     Abstract available


  75. UEMATSU N, Zhao Y, Kiyomi A, Yuan BO, et al
    Chemo-sensitivity of Two-dimensional Monolayer and Three-dimensional Spheroid of Breast Cancer MCF-7 Cells to Daunorubicin, Docetaxel, and Arsenic Disulfide.
    Anticancer Res. 2018;38:2101-2108.
    PubMed     Text format     Abstract available


  76. JUZENIENE A, Bernoulli J, Suominen M, Halleen J, et al
    Antitumor Activity of Novel Bone-seeking, alpha-emitting (224)Ra-solution in a Breast Cancer Skeletal Metastases Model.
    Anticancer Res. 2018;38:1947-1955.
    PubMed     Text format     Abstract available


  77. PARK HL, Kim KY, Park JS, Shin JE, et al
    Clinicopathological Analysis of Ultrasound-guided Vacuum-assisted Breast Biopsy for the Diagnosis and Treatment of Breast Disease.
    Anticancer Res. 2018;38:2455-2462.
    PubMed     Text format     Abstract available


  78. YU JK, Yue CH, Pan YR, Chiu YW, et al
    Isochlorogenic Acid C Reverses Epithelial-Mesenchymal Transition via Down-regulation of EGFR Pathway in MDA-MB-231 cells.
    Anticancer Res. 2018;38:2127-2135.
    PubMed     Text format     Abstract available


  79. LITWIN M, Szczepanska-Buda A, Michalowska D, Grzegrzolka J, et al
    Aberrant Expression of PIWIL1 and PIWIL2 and Their Clinical Significance in Ductal Breast Carcinoma.
    Anticancer Res. 2018;38:2021-2030.
    PubMed     Text format     Abstract available


  80. NIEMIEC J, Adamczyk A, Harazin-Lechowska A, Ambicka A, et al
    Podoplanin-positive Cancer-associated Stromal Fibroblasts in Primary Tumor and Synchronous Lymph Node Metastases of HER2-overexpressing Breast Carcinomas.
    Anticancer Res. 2018;38:1957-1965.
    PubMed     Text format     Abstract available


    March 2018
  81. GOMES I, Miranda A, Nunes C
    Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012.
    Anticancer Res. 2018;38:1797-1805.
    PubMed     Text format     Abstract available


  82. ALEXOPOULOU E, Katsila T, Tolia M, Tsoukalas N, et al
    An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.
    Anticancer Res. 2018;38:1615-1622.
    PubMed     Text format     Abstract available


  83. FRITZ P, Dippon J, Muller S, Goletz S, et al
    Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
    Anticancer Res. 2018;38:1585-1593.
    PubMed     Text format     Abstract available


  84. KOI Y, Koga C, Akiyoshi S, Masuda T, et al
    Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
    Anticancer Res. 2018;38:1579-1584.
    PubMed     Text format     Abstract available


  85. DIMAS DT, Perlepe CD, Sergentanis TN, Misitzis I, et al
    The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1551-1562.
    PubMed     Text format     Abstract available


  86. DE CREMOUX P, Hamy AS, Lehmann-Che J, Scott V, et al
    COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
    Anticancer Res. 2018;38:1485-1490.
    PubMed     Text format     Abstract available


  87. HA GH, Kim DY, Breuer EK, Kim CK, et al
    Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2018;38:1303-1310.
    PubMed     Text format     Abstract available


  88. UJHELYI M, Pukancsik D, Kelemen P, Kovacs E, et al
    Barriers to Organized Mammography Screening Programs in Hungary: A Questionnaire-based Study of 3,313 Women.
    Anticancer Res. 2018;38:1727-1734.
    PubMed     Text format     Abstract available


  89. EL HAGE CHEHADE H, Mokbel K
    Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision?
    Anticancer Res. 2018;38:1263-1266.
    PubMed     Text format     Abstract available


    February 2018
  90. FRIEDRICH M, Reichert K, Woeste A, Polack S, et al
    Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
    Anticancer Res. 2018;38:1201-1207.
    PubMed     Text format     Abstract available


  91. FUJII T, Horiguchi J, Yanagita Y, Koibuchi Y, et al
    Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
    Anticancer Res. 2018;38:905-909.
    PubMed     Text format     Abstract available


  92. NAWA-NISHIGAKI M, Kobayashi R, Suzuki A, Hirose C, et al
    Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:877-884.
    PubMed     Text format     Abstract available


  93. GERA R, Mokbel R, Igor I, Mokbel K, et al
    Does the Use of Hair Dyes Increase the Risk of Developing Breast Cancer? A Meta-analysis and Review of the Literature.
    Anticancer Res. 2018;38:707-716.
    PubMed     Text format     Abstract available


  94. BELKACEMI L, Atkins JL, Yang LU, Gadgil P, et al
    Phosphaplatin Anti-tumor Effect Enhanced by Liposomes Partly via an Up-regulation of PEDF in Breast Cancer.
    Anticancer Res. 2018;38:623-646.
    PubMed     Text format     Abstract available


  95. LUCZYNSKA E, Niemiec J, Heinze S, Adamczyk A, et al
    Intensity and Pattern of Enhancement on CESM: Prognostic Significance and its Relation to Expression of Podoplanin in Tumor Stroma - A Preliminary Report.
    Anticancer Res. 2018;38:1085-1095.
    PubMed     Text format     Abstract available


  96. NIEDER C, Kampe TA, Engljahringer K
    Does Patient-reported Dyspnea Reflect Thoracic Disease Characteristics in Patients with Incurable Cancer?
    Anticancer Res. 2018;38:901-904.
    PubMed     Text format     Abstract available


    January 2018
  97. SVOBODOVA S, Kucera R, Fiala O, Marie K, et al
    CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer.
    Anticancer Res. 2018;38:465-469.
    PubMed     Text format     Abstract available


  98. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Mesenchymal-epithelial Transition and Tumor Vascular Remodeling in Eribulin Chemotherapy for Breast Cancer.
    Anticancer Res. 2018;38:401-410.
    PubMed     Text format     Abstract available


  99. TAKASHIMA T, Kawajiri H, Nishimori T, Tei S, et al
    Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2018;38:379-383.
    PubMed     Text format     Abstract available


  100. CHAMARAUX-TRAN TN, Mathelin C, Aprahamian M, Joshi GP, et al
    Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.
    Anticancer Res. 2018;38:95-105.
    PubMed     Text format     Abstract available


  101. JARDEL P, Vignot S, Cutuli B, Creisson A, et al
    Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review.
    Anticancer Res. 2018;38:23-31.
    PubMed     Text format     Abstract available


    December 2017
  102. PESSINA F, Navarria P, Cozzi L, Franceschini D, et al
    Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Anticancer Res. 2017;37:7057-7062.
    PubMed     Text format     Abstract available


  103. YAMANOUCHI K, Kuba S, Sakimura C, Morita M, et al
    The Relationship Between Peripheral Neuropathy Induced by Docetaxel and Systemic Inflammation-based Parameters in Patients with Breast Cancer.
    Anticancer Res. 2017;37:6947-6951.
    PubMed     Text format     Abstract available


  104. MOKBEL K, Wazir U, El Hage Chehade H, Manson A, et al
    A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Anticancer Res. 2017;37:6863-6869.
    PubMed     Text format     Abstract available


  105. NIMEUS E, Folkesson E, Nodin B, Hartman L, et al
    Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups.
    Anticancer Res. 2017;37:6845-6853.
    PubMed     Text format     Abstract available


  106. AULA H, Skytta T, Tuohinen S, Luukkaala T, et al
    Adjuvant Breast Cancer Treatments Induce Changes in Homoarginine Level - A Prospective Observational Study.
    Anticancer Res. 2017;37:6815-6824.
    PubMed     Text format     Abstract available


  107. PEREIRA MC, Mohammed R, VAN Otterlo WAL, DE Koning CB, et al
    Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.
    Anticancer Res. 2017;37:6749-6759.
    PubMed     Text format     Abstract available


  108. STOPE MB, Weiss M, Koensgen D, Popp SL, et al
    Y-box Binding Protein-1 Enhances Oncogenic Transforming Growth Factor beta Signaling in Breast Cancer Cells via Triggering Phospho-Activation of Smad2.
    Anticancer Res. 2017;37:6745-6748.
    PubMed     Text format     Abstract available


  109. MATSUI C, Takatani-Nakase T, Maeda S, Nakase I, et al
    Potential Roles of GLUT12 for Glucose Sensing and Cellular Migration in MCF-7 Human Breast Cancer Cells Under High Glucose Conditions.
    Anticancer Res. 2017;37:6715-6722.
    PubMed     Text format     Abstract available


  110. KAR A, Liu B, Gutierrez-Hartmann A
    ESE-1 Knockdown Attenuates Growth in Trastuzumab-resistant HER2(+) Breast Cancer Cells.
    Anticancer Res. 2017;37:6583-6591.
    PubMed     Text format     Abstract available


  111. SPARTALIS E, Tsilimigras DI, Charalampoudis P, Karachaliou GS, et al
    The "Yin and Yang" of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer.
    Anticancer Res. 2017;37:6557-6562.
    PubMed     Text format     Abstract available


  112. MIRKA H, Tupy R, Narsanska A, Hes O, et al
    Pre-surgical Multiparametric Assessment of Breast Lesions Using 3-Tesla Magnetic Resonance.
    Anticancer Res. 2017;37:6965-6970.
    PubMed     Text format     Abstract available


  113. SAPINHO G, Alho I, Bicho M, Coelho C, et al
    Total Knockdown of LMW-PTP in MDA-MB-231 Cells Reduces Osteoclastogenesis.
    Anticancer Res. 2017;37:6671-6677.
    PubMed     Text format     Abstract available


  114. MANOUCHEHRI JM, Kalafatis M
    Sensitization of rhTRAIL-resistant Triple-negative Breast Carcinoma Through Silibinin Co-Treatment.
    Anticancer Res. 2017;37:6593-6599.
    PubMed     Text format     Abstract available


  115. CHRISTOPOULOS PF, Vlachogiannis NI, Vogkou CT, Koutsilieris M, et al
    The Role of the Androgen Receptor Signaling in Breast Malignancies.
    Anticancer Res. 2017;37:6533-6540.
    PubMed     Text format     Abstract available


    November 2017
  116. MATSUI A, Tatibana A, Suzuki N, Hirata M, et al
    Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Anticancer Res. 2017;37:6481-6488.
    PubMed     Text format     Abstract available


  117. SHEIKH IA, Jiffri EH, Kamal MA, Ashraf GM, et al
    Lactoperoxidase, an Antimicrobial Milk Protein, as a Potential Activator of Carcinogenic Heterocyclic Amines in Breast Cancer.
    Anticancer Res. 2017;37:6415-6420.
    PubMed     Text format     Abstract available


  118. SHEIKH IA, Beg MA, Yasir M
    Molecular Interactions of Carcinogenic Aromatic Amines, 4-Aminobiphenyl and 4,4'-Diaminobiphenyl, with Lactoperoxidase - Insight to Breast Cancer.
    Anticancer Res. 2017;37:6245-6249.
    PubMed     Text format     Abstract available


  119. JEON D, Kim H, Nam K, Oh S, et al
    Cytotoxic Effect of Nano-SiO2 in Human Breast Cancer Cells via Modulation of EGFR Signaling Cascades.
    Anticancer Res. 2017;37:6189-6197.
    PubMed     Text format     Abstract available


  120. WAKIMOTO R, Ono M, Takeshima M, Higuchi T, et al
    Differential Anticancer Activity of Pterostilbene Against Three Subtypes of Human Breast Cancer Cells.
    Anticancer Res. 2017;37:6153-6159.
    PubMed     Text format     Abstract available


  121. DU J, Sun Y, Lu YY, Lau E, et al
    Berberine and Evodiamine Act Synergistically Against Human Breast Cancer MCF-7 Cells by Inducing Cell Cycle Arrest and Apoptosis.
    Anticancer Res. 2017;37:6141-6151.
    PubMed     Text format     Abstract available


    October 2017
  122. SHOJI F, Yamashita N, Inoue Y, Kozuma Y, et al
    Surgical Resection and Outcome of Synchronous and Metachronous Primary Lung Cancer in Breast Cancer Patients.
    Anticancer Res. 2017;37:5871-5876.
    PubMed     Text format     Abstract available


  123. KARMAKAR MK, Samy W, Lee A, Li JW, et al
    Survival Analysis of Patients with Breast Cancer Undergoing a Modified Radical Mastectomy With or Without a Thoracic Paravertebral Block: a 5-Year Follow-up of a Randomized Controlled Trial.
    Anticancer Res. 2017;37:5813-5820.
    PubMed     Text format     Abstract available


  124. HE K, Wang X, Guan X, Yu Q, et al
    Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2017;37:5647-5653.
    PubMed     Text format     Abstract available


  125. KASHIWAGI S, Asano Y, Goto W, Takada K, et al
    Using TILs to Predict Therapeutic Effect of Chemotherapy (Pertuzumab, Trastuzumab, Docetaxel) on HER2-positive Breast Cancer.
    Anticancer Res. 2017;37:5623-5630.
    PubMed     Text format     Abstract available


  126. CHU QD, Zhou M, Medeiros KL, Peddi P, et al
    Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (>/=70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
    Anticancer Res. 2017;37:5585-5594.
    PubMed     Text format     Abstract available


  127. PHAM DH, Kim JS, Kim SK, Shin DJ, et al
    Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells In Vitro.
    Anticancer Res. 2017;37:5507-5513.
    PubMed     Text format     Abstract available


  128. BOBIN-DUBIGEON C, Chauvin A, Brillaud-Meflah V, Boiffard F, et al
    Liver X Receptor (LXR)-regulated Genes of Cholesterol Trafficking and Breast Cancer Severity.
    Anticancer Res. 2017;37:5495-5498.
    PubMed     Text format     Abstract available


  129. CALIS IU, Cosan DT, Mutlu F
    Effects of S1P1 and S1P3 in ER+ and ER- Breast Cancer Cells.
    Anticancer Res. 2017;37:5469-5475.
    PubMed     Text format     Abstract available


  130. GIGLI S, Amabile MI, DI Pastena F, DE Luca A, et al
    Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature.
    Anticancer Res. 2017;37:5395-5398.
    PubMed     Text format     Abstract available


  131. HARUNA F, Lipsett A, Marignol L
    Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Anticancer Res. 2017;37:5343-5353.
    PubMed     Text format     Abstract available


  132. GLASSMAN D, Hignett S, Rehman S, Linforth R, et al
    Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update.
    Anticancer Res. 2017;37:5329-5341.
    PubMed     Text format     Abstract available


  133. GRZEGRZOLKA J, Wojtyra P, Biala M, Piotrowska A, et al
    Correlation Between Expression of Twist and Podoplanin in Ductal Breast Carcinoma.
    Anticancer Res. 2017;37:5485-5493.
    PubMed     Text format     Abstract available


    September 2017
  134. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    Safety for Repeat Lumpectomy Without Radiotherapy for Ipsilateral Breast Tumor Recurrence.
    Anticancer Res. 2017;37:5293-5299.
    PubMed     Text format     Abstract available


  135. EICHLER C, Abrar S, Puppe J, Arndt M, et al
    Detection of Ductal Carcinoma In Situ by Ultrasound and Mammography: Size-dependent Inaccuracy.
    Anticancer Res. 2017;37:5065-5070.
    PubMed     Text format     Abstract available


  136. FUJII T, Yanai K, Tokuda S, Nakazawa Y, et al
    Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings.
    Anticancer Res. 2017;37:5053-5056.
    PubMed     Text format     Abstract available


  137. UEHARA S, Saito K, Asami H, Ohta Y, et al
    Role of ARHGAP24 in ADP Ribosylation Factor 6 (ARF6)-dependent Pseudopod Formation in Human Breast Carcinoma Cells.
    Anticancer Res. 2017;37:4837-4844.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: